The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors,
Most of the recalls are contamination or allergen-based. While 2025 is near, there are still callbacks to be aware of. Here is a list of December recalls according to the FDA. FDA
The U.S. Food and Drug Administration (FDA) recently finalized its long-awaited rule redefining the use of the term “healthy” on food packaging.
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the
On December 27, 2024, the U.S. Food and Drug Administration (FDA) published a final rule updating the criteria regarding when foods may be
BLAIR COUNTY, Pa (WJAC) — The U.S. Food and Drug Administration (FDA) has issued a temporary recall of the latest Gardners Candies' specialty candy bars. According to the announcement, the Blair County-based candy company is recalling its new "Cappuccino Meltaway" bars due to an undeclared tree nut allergen and packaging issue.
The U.S. Food and Drug Administration (FDA) now classifies eggs as a “healthy, nutrient-dense" food, according to a new proposed rule. Registered dietitians react to the change.
The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
The U.S. Food and Drug Administration redefined its parameters for “healthy” food for the first time in 30 years.
Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two new clinical trials.